DCE-MRI assessment of response to neoadjuvant SABR in early stage breast cancer: Comparisons of single versus three fraction schemes and two different imaging time delays post-SABR.
Breast cancer
DCE-MRI
Response assessment
SABR
Tofts model
Journal
Clinical and translational radiation oncology
ISSN: 2405-6308
Titre abrégé: Clin Transl Radiat Oncol
Pays: Ireland
ID NLM: 101713416
Informations de publication
Date de publication:
Mar 2020
Mar 2020
Historique:
received:
18
12
2019
accepted:
22
12
2019
entrez:
6
2
2020
pubmed:
6
2
2020
medline:
6
2
2020
Statut:
epublish
Résumé
To determine the effect of dose fractionation and time delay post-neoadjuvant stereotactic ablative radiotherapy (SABR) on dynamic contrast-enhanced (DCE)-MRI parameters in early stage breast cancer patients. DCE-MRI was acquired in 17 patients pre- and post-SABR. Five patients were imaged 6-7 days post-21 Gy/1fraction (group 1), six 16-19 days post-21 Gy/1fraction (group 2), and six 16-18 days post-30 Gy/3 fractions every other day (group 3). DCE-MRI scans were performed using half the clinical dose of contrast agent. Changes in the surrounding tissue were quantified using a signal-enhancement threshold metric that characterizes changes in signal-enhancement volume (SEV). Tumour response was quantified using K All group 1 and 4/6 group 2 patients' SEV increased post-SABR. All group 3 patients' SEV decreased. The mean K Kinetic parameters measured 2.5 weeks post-SABR in both single fraction and three fraction groups were indicative of response but only the single fraction protocol led to enhancement in the surrounding tissue. Our results also suggest that DCE-MRI one-week post-SABR may be too early for response assessment, at least for single fraction SABR, whereas 2.5 weeks appears sufficiently long to minimize confounding acute effects.
Identifiants
pubmed: 32021911
doi: 10.1016/j.ctro.2019.12.004
pii: S2405-6308(19)30117-X
pmc: PMC6993055
doi:
Types de publication
Journal Article
Langues
eng
Pagination
25-31Informations de copyright
© 2019 The Author(s).
Déclaration de conflit d'intérêts
The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Neuro Oncol. 2018 Mar 27;20(4):567-575
pubmed: 29016814
Magn Reson Imaging. 2012 Nov;30(9):1323-41
pubmed: 22770690
Radiat Res. 2015 Jun;183(6):713-21
pubmed: 26010711
Magn Reson Imaging. 2016 May;34(4):496-501
pubmed: 26708031
J Magn Reson Imaging. 2018 Jan;47(1):191-199
pubmed: 28480541
PLoS One. 2018 Aug 16;13(8):e0202387
pubmed: 30114235
Lancet Neurol. 2017 Jul;16(7):564-570
pubmed: 28653648
Radiat Res. 2012 Mar;177(3):311-27
pubmed: 22229487
PLoS One. 2018 Nov 26;13(11):e0207933
pubmed: 30475887
Physiol Chem Phys Med NMR. 1984;16(2):167-72
pubmed: 6505043
World J Methodol. 2014 Jun 26;4(2):46-58
pubmed: 25332905
Nat Rev Cancer. 2015 Jul;15(7):409-25
pubmed: 26105538
Radiat Oncol. 2008 Oct 31;3:36
pubmed: 18976463
Radiat Oncol. 2010 Oct 04;5:90
pubmed: 20920346
Magn Reson Med. 2010 Aug;64(2):439-46
pubmed: 20665788
Int J Clin Oncol. 2014 Aug;19(4):570-8
pubmed: 24993673
J Med Imaging Radiat Oncol. 2015 Apr;59(2):207-15
pubmed: 25601133
Spine J. 2016 Mar;16(3):291-8
pubmed: 26325017
Med Phys. 2017 Sep;44(9):4758-4765
pubmed: 28622420
Magn Reson Med. 2003 Mar;49(3):515-26
pubmed: 12594755
IEEE Trans Med Imaging. 2003 Jan;22(1):120-8
pubmed: 12703765
Magn Reson Med. 2007 Jan;57(1):192-200
pubmed: 17191242
Radiographics. 2011 Nov-Dec;31(7):2059-91
pubmed: 22084189
Adv Radiat Oncol. 2016 Jul 01;1(3):194-203
pubmed: 28740888
Int J Radiat Oncol Biol Phys. 2017 Mar 15;97(4):747-753
pubmed: 28244410
Semin Radiat Oncol. 2011 Apr;21(2):147-56
pubmed: 21356482
Med Image Anal. 2012 Oct;16(7):1423-35
pubmed: 22722056
JACC Basic Transl Sci. 2018 Aug 28;3(4):563-572
pubmed: 30175280
Magn Reson Med. 2006 Nov;56(5):993-1000
pubmed: 17036301
Radiother Oncol. 2019 Feb;131:60-65
pubmed: 30773188
AJR Am J Roentgenol. 2013 Jan;200(1):8-19
pubmed: 23255736
Radiother Oncol. 2015 Jan;114(1):42-9
pubmed: 25480094
J Magn Reson Imaging. 1999 Sep;10(3):223-32
pubmed: 10508281
Technol Cancer Res Treat. 2016 Oct;15(5):651-60
pubmed: 26134438
Front Oncol. 2014 Jan 21;4:1
pubmed: 24478982
Invest Radiol. 2006 Mar;41(3):213-21
pubmed: 16481903
Lancet Oncol. 2003 Sep;4(9):529-36
pubmed: 12965273
Radiother Oncol. 2010 Feb;94(2):156-60
pubmed: 20080311